Matt Crawford

Today, we took long-overdue action to restore science, accountability, and the rule of law. In September 2023, the Biden FDA pushed a number of peptides into Category 2 — “Bulk Drug Substances that Raise Significant Safety Risks” — driving a dangerous black market that puts Americans at risk. Now, after nominators withdrew 12 peptides, the FDA will remove them from Category 2 and will bring them to PCAC at its next two meetings, beginning in July—where independent experts will rigorously evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence. • BPC-157 • Thymosin beta-4 fragment (LKKTETQ) • Epitalon • GHK-Cu (injectable) • MOTS-c • DSIP (Emideltide) • Dihexa Acetate • Ibutamoren Mesylate • Melanotan II • KPV • Semax (heptapeptide) • Cathelicidin LL-37 This action begins to restore regulated access and will immediately begin shifting demand away from the black market. We will follow the science, enforce the law, and deliver the clarity patients, providers, and pharmacies deserve.

Some of my favorite names are currently underperforming for different reasons that are not bad fundamentals and that is exactly why I am interested. $ASTS is AST SpaceMobile, building the first space based cellular broadband network designed to connect ordinary smartphones directly to satellites with no special hardware. The BlueBird constellation aims to deliver true direct to device coverage across dead zones worldwide, with carrier partnerships already in place. The weakness is mechanical not fundamental. Since the SpaceX IPO, space names have been bundled into a basket that insiders are shorting to lock in gains, and ASTS gets dragged down with the group regardless of its own progress. That dislocation is the opportunity. $AAOI is Applied Optoelectronics, a vertically integrated maker of optical transceivers and networking components for hyperscale data centers, cable broadband, and telecom. As AI buildouts push bandwidth demand higher, its optics sit directly in the path of that spend. The overhang here is the roughly 600M ATM facility weighing on the stock as the market braces for dilution. That pressure should clear once the raise runs its course, and I expect the supply side drag to be largely finished soon, leaving the fundamentals to reassert. $ONDS, $KRKNF / $PNG.V and $EOS.AX span autonomous drone platforms, marine robotics and directed energy counter UAS systems, three corners of a defense complex being rearmed for a more contested world. Each occupies a real niche rather than chasing a crowded category. Defense simply is not a hot sector for capital right now, which is precisely why these are cheap. The fundamentals are sound and the positioning is strong for where spending is headed, so the patience tax today looks like a discount rather than a warning. I see all of those as very attractive entries here Will revisit in a month

$ASTS rejected from the final Log downtrend line yesterday and again this morning (red circles) after breaking out and retesting the original log wedge (green circle) Also, yesterday and today's rejection lined up with 5 and 50D SMA. 10 and 100D at $90.5. Big upside above $91!

$ASTS: It definitely looks like hedge funds are going long $SPCX and shorting $ASTS and other space names. Real-time short interest has hit an all-time high at 72.2M. These guys are going to be our rocket fuel for the next big leg higher. 6/16: 72.2M 6/15: 71.4M 6/12: 66.5M 6/11: 64.8M 6/10: 64.1M